Indexes | Current issue | Disclaimer
Table of contents | Full text PDF (190 KB) | Previous article | Next article
Monica M Lahra, Rodney P Enriquez for the Australian Meningococcal Surveillance Programme
Introduction
The reference laboratories of the National Neisseria Network, Australia report laboratory data on invasive meningococcal disease (IMD) cases confirmed by laboratory testing using culture and non-culture based techniques for the Australian Meningococcal Surveillance Programme. Culture positive cases, where Neisseria meningitidis is grown from a normally sterile site or skin lesions, and non-culture based diagnoses, derived from results of nucleic acid amplification testing and serological techniques, are defined as IMD according to Public Health Laboratory Network definitions. Data contained in quarterly reports are usually restricted to a description of the numbers of cases by jurisdiction and serogroup, where known.
Results
Of note in this quarter 2016 is the number and proportion of IMD caused by serogroup W. In the years 2007 to 2011 the proportion of IMD caused by serogroup W in Australia ranged from 1.8% to 4.5%, and increased to 8.6% to 9.9% in 2013 to 2014. In 2015, this increased markedly to 31/81 (21.4%) of the IMD in Australia. In 2015, 25/31 serogroup W IMD strains were genotyped, and 81% were sequence type (ST)-11, and had the porA antigen encoding gene type P1.5,2, the same genotype as the hypervirulent serogroup W strain reported in the United Kingdom and South America since 2009. Nationally enhanced surveillance strategies, including whole genome sequencing and phylogenetic inference, has been applied to the recent emergence in Australia of N. meningitidis serogroup W in Australia.
State or territory | Year | Serogroup | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
A | B | C | Y | W135 | ND | All | |||||||||
Q2 | YTD | Q2 | YTD | Q2 | YTD | Q2 | YTD | Q2 | YTD | Q2 | YTD | Q2 | YTD | ||
Australian Capital Territory | 2016 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2015 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | |
New South Wales | 2016 | 0 | 0 | 2 | 7 | 0 | 1 | 3 | 4 | 5 | 9 | 0 | 2 | 10 | 23 |
2015 | 0 | 0 | 9 | 12 | 0 | 1 | 2 | 2 | 1 | 2 | 1 | 1 | 13 | 18 | |
Northern Territory | 2016 | 0 | 0 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
2015 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | |
Queensland | 2016 | 0 | 0 | 2 | 5 | 0 | 0 | 2 | 6 | 3 | 5 | 2 | 2 | 9 | 18 |
2015 | 0 | 0 | 4 | 9 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 5 | 11 | |
South Australia | 2016 | 0 | 0 | 5 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 11 |
2015 | 0 | 0 | 7 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 9 | |
Tasmania | 2016 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 |
2015 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Victoria | 2016 | 0 | 0 | 4 | 7 | 0 | 1 | 2 | 2 | 9 | 15 | 0 | 0 | 15 | 25 |
2015 | 0 | 0 | 8 | 16 | 0 | 0 | 2 | 2 | 5 | 6 | 0 | 0 | 15 | 24 | |
Western Australia | 2016 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 1 | 3 | 0 | 0 | 2 | 5 |
2015 | 0 | 0 | 2 | 4 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 3 | 5 | |
Total | 2016 | 0 | 0 | 16 | 34 | 0 | 2 | 7 | 12 | 18 | 34 | 2 | 4 | 43 | 86 |
2015 | 0 | 0 | 32 | 52 | 0 | 1 | 5 | 6 | 6 | 8 | 2 | 2 | 45 | 69 |
Some minor corrections to data in the Table below may be made in subsequent reports if additional data are received. A full analysis of laboratory confirmed cases of IMD in each calendar year is contained in the AMSP annual report published in Communicable Diseases Intelligence. For more information see Commun Dis Intell 2016;40(1):E13.
Author details
Monica M Lahra1,2
Rodney P Enriquez 1
- Neisseria Reference Laboratory and World Health Organisation Collaborating Centre for STD, Sydney. Department of Microbiology, South Eastern Area Laboratory Services, The Prince of Wales Hospital, Randwick, NSW
- School of Medical Sciences, Faculty of Medicine, The University of New South Wales, New South Wales
CDI Search
Communicable Diseases Intelligence subscriptions
Sign-up to email updates: Subscribe Now
Communicable Diseases Surveillance